[{"data":1,"prerenderedAt":126},["ShallowReactive",2],{"drug-tavaborole":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":33,"contraindications":53,"warnings":54,"renal":55,"monitoring":56,"interactions":57,"review":58,"examples":61,"atc":62,"iran":64,"usApproval":71,"links":77,"populations":92},"tavaborole",1,{"fa":7,"en":8},"تاوابورول","Tavaborole","dermatology",{"fa":11,"en":12},"ضدقارچ اکسابورول موضعی","Topical oxaborole antifungal",[14],{"name":15,"market":16},"Kerydin","US",[18,19,7],"kerydin","کریدین",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"sol","solution","topical","5% topical solution",{"amount":5,"unit":27,"perUnit":27},"application",[16],[30],{"source":31,"section":32},"fda-tavaborole","3",[34],{"id":35,"disease":36,"label":37,"population":40,"type":44,"unit":45,"dose":46,"refs":50},"ony","onychomycosis",{"fa":38,"en":39},"اونیکومایکوز ناخن پا — روزانه یک بار روی کل سطح و زیر نوک ناخن، ۴۸ هفته","Toenail onychomycosis — apply once daily to the entire nail surface and under the tip for 48 weeks",{"minAge":41},{"value":42,"unit":43},6,"year","notCalculated","mg",{"reason":47},{"fa":48,"en":49},"فقط موضعی؛ چشمی، خوراکی یا واژینال نه.","Topical only; not ophthalmic, oral or intravaginal.",[51],{"source":31,"section":52},"2",[],[],[],[],[],{"status":59,"reviewer":60,"date":60},"unverified",null,[],[63],"D01AE24",{"status":65,"refs":66},"not-found",[67],{"source":68,"section":69,"url":70},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Tavaborole",{"kind":72,"refs":73,"id":76},"ANDA",[74],{"source":31,"section":75},"SPL approval \u002F marketing category","ANDA211297",[78,81,85,89],{"kind":79,"url":80,"label":76},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=211297",{"kind":82,"url":83,"label":84},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=050f5d10-5591-426e-9020-6516b3363304","FDA Tavaborole",{"kind":86,"url":87,"label":88},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa614049.html","Tavaborole Topical",{"kind":90,"url":91,"label":63},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=D01AE24",{"pregnancy":93,"lactation":102,"pediatric":110,"geriatric":118},{"level":94,"text":95,"quote":98,"refs":99},"caution",{"fa":96,"en":97},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no available data on tavaborole topical solution use in pregnant women to inform a drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes.",[100],{"source":31,"section":101},"8.1",{"level":94,"text":103,"quote":106,"refs":107},{"fa":104,"en":105},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information available on the presence of tavaborole in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production after topical application of tavaborole topical solution to women who are breastfeeding. tavaborole topical solution is systemically …",[108],{"source":31,"section":109},"8.2",{"level":94,"text":111,"quote":114,"refs":115},{"fa":112,"en":113},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of tavaborole topical solution were established in patients 6 years of age and older.",[116],{"source":31,"section":117},"8.4",{"level":94,"text":119,"quote":122,"refs":123},{"fa":120,"en":121},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In clinical trials of 791 subjects who were exposed to tavaborole topical solution, 19% were 65 years of age and over, while 4% were 75 years of age and over.",[124],{"source":31,"section":125},"8.5",1792191568111]